Lim Xin Yi, Ram Sanyogita, Scahill Shane, Barnes Joanne
School of Pharmacy, University of Auckland, 85 Park Rd, Grafton, Auckland, 1023, New Zealand.
Drug Saf. 2025 Aug 8. doi: 10.1007/s40264-025-01587-w.
The natural health products (NHPs) industry is a key stakeholder in pharmacovigilance for NHPs. However, the specific contributions that the NHPs industry makes to pharmacovigilance for NHPs are not well-understood.
This scoping review aimed to identify and map published literature describing the contributions of the NHPs industry to pharmacovigilance activities for NHPs. Assessment of benefit-harm balance for individual NHPs/natural ingredients is outside the scope of this review.
Using predetermined keywords and Medical Subject Headings, seven international electronic biomedical journal databases were searched to identify articles describing the contributions of the NHPs industry to pharmacovigilance for NHPs in relation to product surveillance and stakeholders' views on the NHPs industry and its pharmacovigilance activities.
Of the 2285 records identified, 40 articles (representing 40 studies) met the inclusion criteria for this review. Among these, 33 described post-marketing surveillance activities and seven explored stakeholders' views. Of the articles describing post-marketing surveillance studies, 22 were authored and/or sponsored by the industry; the remaining 11 involved contributions from the NHPs industry in the form of safety data submitted as spontaneous reports to a national or state pharmacovigilance database. Contributions of the NHPs industry were primarily through passive surveillance via spontaneous reporting. In total, 13 active surveillance studies were undertaken by the NHPs industry, mainly in clinical care settings such as medical centres, hospitals, and private practices, and were focused on single products. There were limited findings relating to stakeholders' views on pharmacovigilance and the NHPs industry's involvement.
The NHPs industry contributes to pharmacovigilance for NHPs primarily through passive surveillance measures. Active surveillance involving the NHPs industry was typically undertaken in non-community settings. Additional research exploring stakeholders' views on and preparedness for participating in active surveillance involving the industry, focusing particularly on models based on the consumer-industry reporting pathway, could identify new strategies for strengthening post-marketing safety monitoring for NHPs.
天然健康产品(NHPs)行业是天然健康产品药物警戒的关键利益相关者。然而,人们对天然健康产品行业在天然健康产品药物警戒方面的具体贡献了解不足。
本范围综述旨在识别和梳理已发表的文献,描述天然健康产品行业对天然健康产品药物警戒活动的贡献。对单个天然健康产品/天然成分的利弊平衡评估不在本综述范围内。
使用预先确定的关键词和医学主题词,检索了七个国际电子生物医学期刊数据库,以识别描述天然健康产品行业在产品监测以及利益相关者对天然健康产品行业及其药物警戒活动的看法方面,对天然健康产品药物警戒贡献的文章。
在识别出的2285条记录中,40篇文章(代表40项研究)符合本综述的纳入标准。其中,33篇描述了上市后监测活动,7篇探讨了利益相关者的观点。在描述上市后监测研究的文章中,22篇由行业撰写和/或赞助;其余11篇涉及天然健康产品行业以自发报告形式向国家或州药物警戒数据库提交安全数据所做的贡献。天然健康产品行业的贡献主要通过自发报告的被动监测。天然健康产品行业总共开展了13项主动监测研究,主要在医疗中心、医院和私人诊所等临床护理环境中进行,且集中于单一产品。关于利益相关者对药物警戒及天然健康产品行业参与情况的看法,研究结果有限。
天然健康产品行业主要通过被动监测措施对天然健康产品药物警戒做出贡献。涉及天然健康产品行业的主动监测通常在非社区环境中进行。进一步研究利益相关者对参与涉及该行业的主动监测的看法和准备情况,尤其关注基于消费者 - 行业报告途径的模式,可能会确定加强天然健康产品上市后安全监测的新策略。